ClinicalTrials.gg
CompletedNCT06294912Updated Jan 13, 2025

A Study to Evaluate Antimalarial Activity and Safety of MK-7602 in Healthy Adults (MK-7602-003)

A Phase 1 interventional study of Plasmodium falciparum and MK-7602 in Malaria, sponsored by Merck Sharp & Dohme LLC. Completed at 1 site in Australia. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-01-13.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies in Malaria with a site in Australia — 1 open to participants now, 1 under way, none of them phase 3. Malaria · Australia.

Enrollment
8th of 20
16 · median 14
Started
2024
the only one that year
Phase 1
16 of 20
1 open now
Registered
19th of 20
by date
Lead sponsor
1 of 20
Merck Sharp & Dohme LLC

Among the 20 studies in Malaria with a site in Australia, this one is the 8th largest by enrollment, is the only one that started in 2024, is one of 16 in phase 1, and was the 19th registered.

Malaria

1,185 studies on the registry are indexed under Malaria; 80 are open to participants now.

Browse Malaria studies →

Open to participants now

1 of the 20 studies in Malaria with a site in Australia is open now. Recruiting first, the newest first:

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 52 Malaria studies recruiting now, 15 (29%) set no upper age limit and 34 (65%) stop at 75 or younger; 38 take children under 18; 32 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Malaria with a site in Australia, or all of them as a file.
02

Study summary

The purpose of this study is to assess the antimalarial activity, pharmacokinetics, and safety of MK-7602 in healthy adults following Plasmodium falciparum (P. falciparum) infection.

03

Conditions studied

  • Malaria

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

The main inclusion and exclusion criteria include but are not limited to the following:

Inclusion criteria

Inclusion Criteria:

  • Is in good health
  • Has a (BMI) between 18 and 32 kg/m2, inclusive
  • For participant assigned male sex at birth: If capable of producing sperm, participant must agree to the following during the study treatment period and for at least 90 days after the last dose of MK-7602: Refrain from donating sperm, plus EITHER be abstinent OR must agree to use male condom plus additional method
  • For participant assigned female sex at birth: EITHER be a person of nonchildbearing potential (PONCBP) OR must use a highly effective contraceptive method or be abstinent during the intervention period and for at least 10 days after the last dose of study intervention
  • Must provide confirmation of not living alone (at any stage from inoculation day until the end of the study). A participant who lives alone may be included on a case-by-case basis.
  • Agrees to refrain from eating food containing poppy seeds for 48 hours prior to screening, malaria inoculation, and MK-7602 administration

Exclusion criteria

Exclusion Criteria:

  • History of clinically significant endocrine, gastrointestinal (GI), cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases
  • Is mentally or legally incapacitated or has a history of clinically significant psychiatric disorder
  • History of cancer ()
  • History of malaria
  • History of splenectomy
  • History of ever receiving a blood transfusion
  • History of recurrent headache (eg, tension-type, cluster or migraine) with a frequency of ≥2 episodes per month on average and severe enough to require medical therapy, during the 5 years preceding the screening visit
  • History of convulsion (including intravenous drug or vaccine-induced episodes). A medical history of a single febrile convulsion during childhood is not considered an exclusion criterion.
  • Has presence of clinically significant infectious disease or fever (eg, sublingual temperature ≥38.5 degrees Celsius) within the 5 days prior to inoculation
  • Has evidence of acute illness within the 4 weeks prior to screening that the Investigator deems may compromise participant safety
  • Has clinically significant disease or any condition or disease that might affect drug absorption, distribution, or excretion (eg, gastrectomy, diarrhea)
  • Has a medical requirement for intravenous immunoglobulin or blood transfusions
  • Has had a major surgery with more than 470 mL of blood loss, lost 1 unit of blood (approximately 470 mL) or undergone blood donation of any volume to the Australian Red Cross Blood Service (Blood Service) or other blood blank within 4 weeks prior to the prestudy screening visit) or during the 8 weeks prior to inoculation
  • Has used any , anti-inflammatory drugs (excluding commonly used over-the-counter anti-inflammatory drugs such as ibuprofen, acetylsalicylic acid, diclofenac), immunomodulators or anticoagulants within the past three months
  • History of receiving therapy (including systemic steroids, adrenocorticotrophic hormone, or inhaled steroids) at a dose or duration potentially associated with hypothalamic-pituitary-adrenal axis suppression within the past year from the screening visit
  • Has had any vaccination within the last 28 days
  • Has participated in another study within 12 weeks (or 5 half-lives, whichever is greater) prior to the prestudy (screening) visit
  • History of participation in a previous malaria challenge study or malaria vaccine study.
  • Must not have had malaria exposure that is considered by the principal investigator or their delegate to be significant
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Panel A: MK-7602 Single dose Part 1

    Participants are inoculated with Plasmodium falciparum (P. falciparum). Panel A participants receive MK-7602 as a single oral dose. Participants will receive artemether/lumefantrine oral tablets as definitive antimalarial treatment. Additional definitive antimalarial treatment may be administered at the investigator's discretion.

    Other: Plasmodium falciparum · Drug: MK-7602 · Drug: Artemether/lumefantrine · Drug: Primaquine · Drug: Artesunate · Drug: Atovaquone/proguanil

  • Experimental
    Panel B: MK-7602 Single dose Part 1

    Participants are inoculated with P. falciparum. Panel B participants receive MK-7602 as a single oral dose. Participants will receive artemether/lumefantrine oral tablets as definitive antimalarial treatment. Additional definitive antimalarial treatment may be administered at the investigator's discretion.

    Other: Plasmodium falciparum · Drug: MK-7602 · Drug: Artemether/lumefantrine · Drug: Primaquine · Drug: Artesunate · Drug: Atovaquone/proguanil

  • Experimental
    Panel C: MK-7602 Single dose Part 1

    Participants are inoculated with P. falciparum. Panel C participants receive MK-7602 as a single oral dose. Participants will receive artemether/lumefantrine oral tablets as definitive antimalarial treatment. Additional definitive antimalarial treatment may be administered at the investigator's discretion.

    Other: Plasmodium falciparum · Drug: MK-7602 · Drug: Artemether/lumefantrine · Drug: Primaquine · Drug: Artesunate · Drug: Atovaquone/proguanil

  • Experimental
    Panel D: MK-7602 Single dose Part 1

    Participants are inoculated with P. falciparum. Panel D participants receive MK-7602 as a single oral dose. Participants will receive artemether/lumefantrine oral tablets as definitive antimalarial treatment. Additional definitive antimalarial treatment may be administered at the investigator's discretion.

    Other: Plasmodium falciparum · Drug: MK-7602 · Drug: Artemether/lumefantrine · Drug: Primaquine · Drug: Artesunate · Drug: Atovaquone/proguanil

  • Experimental
    Panel E: MK-7602 Single dose Part 1

    Participants are inoculated with P. falciparum. Panel E participants receive MK-7602 as a single oral dose. Participants will receive artemether/lumefantrine oral tablets as definitive antimalarial treatment. Additional definitive antimalarial treatment may be administered at the investigator's discretion.

    Other: Plasmodium falciparum · Drug: MK-7602 · Drug: Artemether/lumefantrine · Drug: Primaquine · Drug: Artesunate · Drug: Atovaquone/proguanil

  • Experimental
    Panel F: MK-7602 Multiple dose Part 2

    Participants are inoculated with P. falciparum. Panel F participants receive MK-7602 at multiple oral doses. Participants will receive artemether/lumefantrine oral tablets as definitive antimalarial treatment. Additional definitive antimalarial treatment may be administered at the investigator's discretion.

    Other: Plasmodium falciparum · Drug: MK-7602 · Drug: Artemether/lumefantrine · Drug: Primaquine · Drug: Artesunate · Drug: Atovaquone/proguanil

  • Experimental
    Panel G: MK-7602 Multiple dose Part 2

    Participants are inoculated with P. falciparum. Panel G participants receive MK-7602 at multiple oral doses. Participants will receive artemether/lumefantrine oral tablets as definitive antimalarial treatment. Additional definitive antimalarial treatment may be administered at the investigator's discretion.

    Other: Plasmodium falciparum · Drug: MK-7602 · Drug: Artemether/lumefantrine · Drug: Primaquine · Drug: Artesunate · Drug: Atovaquone/proguanil

  • Experimental
    Panel H: MK-7602 Multiple dose Part 2

    Participants are inoculated with P. falciparum. Panel H participants receive MK-7602 at multiple oral doses. Participants will receive artemether/lumefantrine oral tablets as definitive antimalarial treatment. Additional definitive antimalarial treatment may be administered at the investigator's discretion.

    Other: Plasmodium falciparum · Drug: MK-7602 · Drug: Artemether/lumefantrine · Drug: Primaquine · Drug: Artesunate · Drug: Atovaquone/proguanil

Interventions

  • OtherPlasmodium falciparum

    Parasite inoculation administered by intravenous (IV) infusion as the challenge agent

    Also known as: P. falciparum

  • Capsules to be administered orally.

  • DrugArtemether/lumefantrine

    Drug pages: Artemether · Lumefantrine

    Tablets to be administered orally as definitive antimalarial treatment.

    Also known as: Riamet®; Coartem®

  • Tablets to be administered orally as definitive antimalarial treatment.

    Also known as: Primacin®

  • Intravenous (IV) infusion to be administered as definitive antimalarial treatment.

  • DrugAtovaquone/proguanil

    Drug pages: Atovaquone · Proguanil

    Tablets to be administered orally as definitive antimalarial treatment.

    Also known as: Malarone ®

06

What researchers measure

Primary outcomes

  1. Parasite reduction ratio (PRR48) (Parts 1 and 2)

    PRR48 is the logarithm of the parasite reduction ratio per 48 hours determined from parasitemia data from time 0 to time 48 hours. Blood samples collected pre-dose and at multiple timepoints post-dose will be used to determine the PRR48.

    Time frame: Pre-inoculation on Day 0, once daily Days 4 to 7, pre-dose of MK-7602 on Day 8, post-first dose of MK-7602 at 2, 4, 8, 12, 16, 24, 30, 36, 48, 54, 60, 72, (78 Part 2 only), 84, and 96 hours, and once daily Days 13, 15, 17, 20, 22, 24, 27, 29, 31, and 34

  2. Parasite Clearance Half-life (PCt1/2) (Parts 1 and 2)

    PCt1/2 is the half-life of the log-linear portion of the parasite clearance curve. Blood samples collected pre-dose and at multiple timepoints post-dose will be used to determine the PCt1/2.

    Time frame: Pre-inoculation on Day 0, once daily Days 4 to 7, pre-dose of MK-7602 on Day 8, post-first dose of MK-7602 at 2, 4, 8, 12, 16, 24, 30, 36, 48, 54, 60, 72, (78 Part 2 only), 84, and 96 hours, and once daily Days 13, 15, 17, 20, 22, 24, 27, 29, 31, and 34

  3. Parasite Regrowth (Parts 1 and 2)

    Parasite regrowth is defined as initial parasite clearance followed by asexual parasite regrowth above 5,000 parasites/mL. Blood samples collected pre-dose and at multiple timepoints post-dose will be used to determine the parasite regrowth.

    Time frame: Pre-inoculation on Day 0, once daily Days 4 to 7, pre-dose of MK-7602 on Day 8, post-first dose of MK-7602 at 2, 4, 8, 12, 16, 24, 30, 36, 48, 54, 60, 72, (78 Part 2 only), 84, and 96 hours, and once daily Days 13, 15, 17, 20, 22, 24, 27, 29, 31, and 34

  4. Part 1 Single dose: Area Under the Concentration-Time Curve Extrapolated to Infinity (AUC0-inf) of MK-7602

    Blood samples collected pre-dose and at multiple timepoints post-dose will be used to determine the AUC0-inf for Part 1.

    Time frame: Pre-dose of MK-7602 on Day 8 and post-dose of MK-7602 at 0.5, 1, 2, 3, 4, 8, 12, 24, 30, 36, 48, 54, 60, 72 and 96 hours and then once daily on Days 13, 15, 17, 20, and 22

  5. Part 1 Single dose: Maximum Plasma Concentration (Cmax) of MK-7602

    Blood samples collected pre-dose and at multiple timepoints post-dose will be used to determine the Cmax for Part 1.

    Time frame: Pre-dose of MK-7602 on Day 8 and post-dose of MK-7602 at 0.5, 1, 2, 3, 4, 8, 12, 24, 30, 36, 48, 54, 60, 72 and 96 hours and then once daily on Days 13, 15, 17, 20, and 22

  6. Part 1 Single dose: Concentration at 24 Hours (C24) of MK-7602

    Blood samples collected pre-dose and at multiple timepoints post-dose will be used to determine the C24 for Part 1.

    Time frame: Pre-dose of MK-7602 on Day 8 and post-dose of MK-7602 at 0.5, 1, 2, 3, 4, 8, 12, 24, 30, 36, 48, 54, 60, 72 and 96 hours and then once daily on Days 13, 15, 17, 20, and 22

  7. Part 1 Single dose: Time to Maximum Plasma Concentration (Tmax) of MK-7602

    Blood samples collected pre-dose and at multiple timepoints post-dose will be used to determine the Tmax for Part 1.

    Time frame: Pre-dose of MK-7602 on Day 8 and post-dose of MK-7602 at 0.5, 1, 2, 3, 4, 8, 12, 24, 30, 36, 48, 54, 60, 72 and 96 hours and then once daily on Days 13, 15, 17, 20, and 22

  8. Part 1 Single dose: Elimination Half-life (t1/2) of MK-7602

    Blood samples collected pre-dose and at multiple timepoints post-dose will be used to determine the t1/2 for Part 1.

    Time frame: Pre-dose of MK-7602 on Day 8 and post-dose of MK-7602 at 0.5, 1, 2, 3, 4, 8, 12, 24, 30, 36, 48, 54, 60, 72 and 96 hours and then once daily on Days 13, 15, 17, 20, and 22

  9. Part 2 Multiple dose: Area Under the Curve Time 0 to End of the Dosing Interval (AUC0-tau) of MK-7602

    Blood samples collected pre-dose and at multiple timepoints post-dose will be used to determine the AUC0-tau for Part 2.

    Time frame: Pre-dose of MK-7602 on Day 8 and post-first dose of MK-7602 at 0.5, 1, 2, 3, 4, 8, 12, 24, 30, 36, 48, 54, 60, 72, 78, 84 and 96 hours and then once daily on Days 13, 15, 17, 20, and 22

  10. Part 2 Multiple dose: Maximum Plasma Concentration (Cmax) of MK-7602

    Blood samples collected pre-dose and at multiple timepoints post-dose will be used to determine the Cmax for Part 2.

    Time frame: Pre-dose of MK-7602 on Day 8 and post-first dose of MK-7602 at 0.5, 1, 2, 3, 4, 8, 12, 24, 30, 36, 48, 54, 60, 72, 78, 84 and 96 hours and then once daily on Days 13, 15, 17, 20, and 22

  11. Part 2 Multiple dose: Time to Maximum Plasma Concentration (Tmax) of MK-7602

    Blood samples collected pre-dose and at multiple timepoints post-dose will be used to determine the Tmax for Part 2.

    Time frame: Pre-dose of MK-7602 on Day 8 and post-first dose of MK-7602 at 0.5, 1, 2, 3, 4, 8, 12, 24, 30, 36, 48, 54, 60, 72, 78, 84 and 96 hours and then once daily on Days 13, 15, 17, 20, and 22

  12. Part 2 Multiple dose: Elimination Half-life (t1/2) of MK-7602

    Blood samples collected pre-dose and at multiple timepoints post-dose will be used to determine the t½ for Part 2.

    Time frame: Pre-dose of MK-7602 on Day 8 and post-first dose of MK-7602 at 0.5, 1, 2, 3, 4, 8, 12, 24, 30, 36, 48, 54, 60, 72, 78, 84 and 96 hours and then once daily on Days 13, 15, 17, 20, and 22

Secondary outcomes

  1. Number of Participants Who Experience an Adverse Event (AE)

    An AE is defined as any untoward medical occurrence associated with the use of a drug in a participant, whether or not considered drug related. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product and does not imply any judgment about causality.

    Time frame: Up to Day 45

  2. Number of Participants Who Discontinue Study Intervention Due to an AE

    An AE is defined as any untoward medical occurrence associated with the use of a drug in a participant, whether or not considered drug related. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product and does not imply any judgment about causality.

    Time frame: Up to Day 13

07

Study locations

1 site
  • USC Clinical Trials Brisbane (South Bank) ( Site 0001)
    South Brisbane, South Australia 4101, Australia
08

References and documents

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2024 to primary completion in Jan 2025, 8 months.

Of 29 industry-sponsored phase 1 interventional studies under Malaria, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 18. This study's 8 months is below that.

Counting every sponsor, half of 93 studies reached it within 13 months; a quarter within 7 and three quarters within 20.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 28, 2024
First posted
Mar 6, 2024
StartActual
Apr 18, 2024
Primary completionActual
Jan 6, 2025
CompletionActual
Jan 6, 2025
Last update
Jan 13, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 13, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06294912
Responsible party
Sponsor
First posted
Mar 6, 2024
Start date
Apr 18, 2024
Primary completion
Jan 6, 2025
Completion
Jan 6, 2025
Last update
Jan 13, 2025

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: MK-7602

Start the discussion